Voltar à classificação

iRhythm Technologies, Inc. (IRTC)

Valor Justo
HealthcareMedical DevicesUnited States

Fundamental

43

Preço

$111.79

Capitalização de Mercado

$3.75B

Parte 1 · Quanto vale a empresa

Visão Geral

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18 de setembro de 2026 with claude-haiku-4-5 — shared with all users

P/E: 17.7Score: 73Market cap: $63.93B

Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.

P/E: —Score: 51Market cap: $12.14B

Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.

P/E: 15.7Score: 56Market cap: $30.20B

GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.

Koninklijke Philips N.V. (Royal Philips)PHG

Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.

Medtronic plcMDT

Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.

VitalConnect, Inc.Not tracked

This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.

Balanço & Liquidez

Receita

$825M

Últimos 12 meses (até 30/06/2026)

Resultado Líquido

$-14M

Últimos 12 meses (até 30/06/2026)

Fluxo de Caixa Livre

$35M

Capital Próprio Total

$153M

Passivo Total

$867M

Rácio de Liquidez

3.85

Cobertura de Juros

1.89

Dívida/EBITDA

-

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

Caso geralJustamente Valorizada

Valor Justo

$104.37

Preço Atual

$111.79

Margem de Segurança

-7.1%

Intervalo de Valor Justo

$67.84 - $140.89

Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.

Métodos de Estimativa

Preço-alvo dos analistas:$176.14
Fluxo de caixa descontado (DCF):$14.64
Multiplicador de lucros (P/E):Dados insuficientes para o calcular
Fórmula de crescimento de Graham:Dados insuficientes para o calcular
Valor da capacidade de gerar lucro (EPV):Dados insuficientes para o calcular
P/B justificado:Dados insuficientes para o calcular
Desconto de dividendos (Gordon):Dados insuficientes para o calcular
P/FFO, fundos de operações:Dados insuficientes para o calcular
Lucros de meio de ciclo:Dados insuficientes para o calcular
Multiplicador sobre as receitas:$98.85
Consenso dos Analistas:Compra Forte (20B / 1H / 0S)
Última Surpresa de Resultados:+12988.89%

Métricas de Avaliação

Rácio P/E

-

ROE

-29.2%

Rácio P/B

20.14

P/FCF

96.12

Margem Bruta

71.5%

ROIC

-2.2%

Radar de Rentabilidade

Criação de Valor (Vantagem Competitiva)

ROIC

-2.2%

WACC

10.5%

ROIC − WACC

-12.7 pp

O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.

Critérios de Análise Fundamental

Aprovado (12)

  • EPS shows upward trend
  • Price CAGR 14.06%
  • Gross Margin 71.5%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Low reliance on intangibles
  • Revenue Growth 5Y 23.0%
  • Analyst Consensus 95% Buy
  • Earnings Surprise avg 3463.2%
  • Net Margin Trend -1.7% vs -14.1%
  • Piotroski F-Score 6/9

Reprovado (10)

  • ROIC -2.2%
  • P/FCF 96.12
  • P/B Ratio 20.14
  • Debt/Equity ratio
  • Operating Margin -3.0%
  • CapEx intensity
  • Return on Tangible Assets
  • DCF valuation (Overvalued)
  • ROE -9.0%
  • Share Dilution 2.7%

Indisponível (5)

  • Dividend Payout NaN%
  • Debt/EBITDA
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

6/9

Sinais mistos: algumas áreas requerem atenção

score
criteria

Qualidade dos Resultados

-

Baixa qualidade: investigar a contabilidade

Diluição de Ações

2.7%

A emitir novas ações, diluindo a participação

Participações institucionais

Governação

Equipa Executiva

NomeCargoIdade
Mr. Quentin S. BlackfordPresident, CEO & Director46
Mr. Daniel G. WilsonCFO & Principal Financial Officer43
Dr. Minang P. Turakhia M.D., M.S.Chief Medical & Scientific Officer and Executive VP of Advanced Technologies51
Mr. Patrick Michael Murphy J.D.Chief Business & Legal Officer46
Mr. Chad M. PattersonChief Commercial and Product Officer43
Mr. Mervin SmithExecutive Vice President of Business Operations50
Mr. Marc RosenbaumSenior VP of Finance & Chief Accounting Officer52
Mr. Brian LawrenceExecutive VP & CTO55
Ms. Lisa PecoraSenior Vice President of Finance & Investor Relations-
Mr. Sean Clinton FreemanExecutive Vice President of Strategy & Corporate Development49

Risco de Auditoria

9

Risco do Conselho

5

Risco de Remuneração

3

Risco dos Direitos dos Acionistas

7

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Documentos

  • Relatório anual (10-K)

    Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.

    Arquivado em 2026-02-19

    Ver documento
  • Relatório trimestral (10-Q)

    Uma atualização sobre o desempenho financeiro dos últimos três meses.

    Arquivado em 2026-08-06

    Ver documento
  • Relatório de fato relevante (8-K)

    Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.

    Arquivado em 2026-09-22

    Ver documento

via SEC EDGAR

Histórico de Resultados

via SEC EDGAR

Latest News

Recent headlines for IRTC, sourced from Markets Gazette.

  • 3d agoPOSITIVE
    JP Morgan forecasts a 20x revenue increase for this AI stock

    JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.

  • 6/16/2026NEGATIVE
    iRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data

    iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.

via Markets Gazette